Menenjit

Pregnancy: Safe if indicated.

Meningococcal ACWY conjugate vaccines are non-live and considered safe during pregnancy.

• Recommended for pregnant travelers requiring vaccination for Hajj/Umrah (Saudi Arabia requirement).

• Limited formal pregnancy studies, but extensive post-marketing experience without safety signals.

• ACIP: "MenACWY may be administered during pregnancy if indicated."

Breastfeeding: Safe — no restrictions.

Meningococcal ACWY conjugate vaccines are inactivated and safe during breastfeeding. No modification to breastfeeding schedule required.

Pediatric use:

• Menveo: licensed from 2 months of age. Infants: multi-dose series.

• Nimenrix: licensed from 6 weeks of age.

• MenQuadfi: licensed from 12 months of age.

• Routine adolescent vaccination (11–12 years) with booster at 16 years (US ACIP).

• Children with asplenia, complement deficiency, or HIV: 2-dose primary series + boosters every 3–5 years.

• MenB vaccines (Bexsero, Trumenba) for serogroup B: separate schedule.

Geriatric use:

• No specific age-related contraindications. Standard single-dose schedule applies.

• Elderly travelers to the African meningitis belt or performing Hajj should receive MenACWY.

• Immune response adequate in healthy elderly adults.

• Asplenic elderly patients: 2-dose series + boosters every 5 years.